Adolor maintained by Merrill at neutral

Adolor Corp. was maintained by Merrill Lynch analyst Eric Ende at a neutral rating following news that CEO Bruce Peacock has resigned and been replaced by chairman David Madden. Merrill sees it as an auspicious event, given the recent approvable letter for its lead drug Entereg in post-operative ileus and uncertainty about the necessary course of trials needed to achieve FDA approval. Adolor shares Tuesday were down $0.12, or 1.21%, at $9.78 on volume of 1,253,866 shares versus the three-month running average of 529,980 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.